Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1163-1167

  Kodaira, M ^a   Takahashi, S ^a   Yamada, S ^a   Ueda, K ^a   Mishima, Y ^a   Takeuchi, K ^b   Yamamoto, N ^b   Ishikawa, Y ^b   Yokoyama, M ^a   Saotome, T ^a   Terui, Y ^a   Hatake, K ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

Bone metastasis; Cancer of unknown primary site; Carboplatin plus paclitaxel

Indexed keywords

ALBUMIN; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANAPLASTIC CARCINOMA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL DECISION MAKING; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; BONE NEOPLASMS; CARCINOMA; COHORT ANALYSIS; EVALUATION STUDY; HEALTH STATUS; MIDDLE AGED; MORTALITY; NEOPLASMS, UNKNOWN PRIMARY; PATHOLOGY; PATHOPHYSIOLOGY; SECONDARY; SURVIVAL; TASK PERFORMANCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; CARCINOMA; COHORT STUDIES; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TASK PERFORMANCE AND ANALYSIS;

EID: 77954024101     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp583     Document Type: Article

References (24)

1. Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist 1997; 2: 142-152.
2. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002; 38(3): 409-413.
3. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329: 257-263.
4. Briasoulis E, Kalofonos H, Bafaloukos D et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18: 3101-3107.
5. Pentheroudakis G, Briasoulis E, Kalofonos HP et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol 2008; 47: 1148-1155.
6. Berry W, Elkordy M, O'Rourke M et al. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: reasonable regimen for community-based clinic? Cancer Invest 2007; 25: 27-31.
7. Hainsworth JD, Erland JB, Kalman LA et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended schedule etoposide. J Clin Oncol 1997; 15: 2385-2393.
8. Huebner G, Link H, Kohne CH et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomized prospective phase II trial. Br J Cancer 2009; 100: 44-49.
9. Golfinopoulos V, Pentheroudakis G, Salanti G et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 2009; 35: 570-573.
10. Ransom DT, Patel SR, Keeney GL et al. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 1990; 66: 1091-1094.
11. Rosen PP. Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancer 1980; 46: 1298-1306.
12. Jesse RH, Perez CA, Fletcher GH. Cervical lymph node metastasis: unknown primary cancer. Cancer 1973; 31: 854-859.
13. van der Gaast A, Verweij J, Henzen-Logmans S et al. Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol 1990; 1: 119-122.
14. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10: 912-922.
15. Seve P, Ray-Coquard I, Trillet-Lenoir V et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006; 107: 2698-2705.
16. Palmeri S, Lorusso V, Palmeri L et al. Cisplatin and gemcitabine with vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer 2006; 107: 2898-2905.
17. Pittman KB, Olver IN, Koczwara B et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer 2006; 95: 1309-1313.
18. Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patient. J Clin Oncol 1994; 12: 1272-1280.
19. Culine S, Kramar A, Saghatchian M et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary. J Clin Oncol 2002; 20: 4679-4683.
20. Seve P, Sawyer M, Hanson J et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 2006; 106: 2058-2066.
21. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243-6249.
22. Herndon JE 2nd, Kornblith AB, Holland JC, Paskett ED. Patient education level as a predictor of survival in lung cancer clinical trials. J Clin Oncol 2008; 26: 4116-4123.
23. Shoup M, Stojadinovic A, Nissan A et al. Prognostic indicators of outcomes in patients with distant metastases from different thyroid carcinoma. J Am Coll Surg 2003; 197: 191-197.
24. Négrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Franxcais d'Immunothérapie. Ann Oncol 2003; 13: 1460-1468.